[1] |
To KW, Reino JJ, Yoo DH, et al. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective. Respirology, 2013; 18, 765−73. doi: 10.1111/resp.12106 |
[2] |
Wang LX, Zhang H, Ruan YZ, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet, 2014; 383, 2057−64. doi: 10.1016/S0140-6736(13)62639-2 |
[3] |
Zhang H, Liu JJ, Du X. Data analysis of new smear-positive pulmonary tuberculosis patients in China in 2005. Chin J Antituberc, 2008; 107−9. (In Chinese |
[4] |
WHO. Global tuberculosis report 2021. Licence: CC BY-NC-SA 3.0 IGO. , 2021. |
[5] |
Wang YS, Zhu WL, Li T, et al. Changes in newly notified cases and control of tuberculosis in China: time-series analysis of surveillance data. Infect Dis Poverty, 2021; 10, 16. doi: 10.1186/s40249-021-00806-7 |
[6] |
Dong Z, Wang QQ, Yu SC, et al. Application of disability-adjusted life years to evaluate the burden and trend of tuberculosis—China, 1990–2019. China CDC Wkly, 2022; 4, 220−5. |
[7] |
Floyd K, Glaziou P, Houben RMGJ, et al. Global tuberculosis targets and milestones set for 2016-2035: definition and rationale. Int J Tuberc Lung Dis, 2018; 22, 723−30. doi: 10.5588/ijtld.17.0835 |
[8] |
Marvi A, Asadi-Aliabadi M, Darabi M, et al. Silent changes of tuberculosis in Iran (2005–2015): a joinpoint regression analysis. J Family Med Prim Care, 2017; 6, 760−5. doi: 10.4103/jfmpc.jfmpc_190_17 |
[9] |
Essien SK, Epp T, Waldner C, et al. Tuberculosis in Canada and the United States: a review of trends from 1953 to 2015. Can J Public Health, 2019; 110, 697−704. doi: 10.17269/s41997-019-00236-x |
[10] |
Dhamnetiya D, Patel P, Jha RP, et al. Trends in incidence and mortality of tuberculosis in India over past three decades: a joinpoint and age–period–cohort analysis. BMC Pulm Med, 2021; 21, 375. doi: 10.1186/s12890-021-01740-y |
[11] |
Van Doren TP, Sattenspiel L. The 1918 influenza pandemic did not accelerate tuberculosis mortality decline in early‐20th century Newfoundland: investigating historical and social explanations. Am J Phys Anthropol, 2021; 176, 179−91. doi: 10.1002/ajpa.24332 |
[12] |
Zuo ZB, Wang MC, Cui HZ, et al. Spatiotemporal characteristics and the epidemiology of tuberculosis in China from 2004 to 2017 by the nationwide surveillance system. BMC Public Health, 2020; 20, 1284. doi: 10.1186/s12889-020-09331-y |
[13] |
Bureau of Disease Control and Prevention, Ministry of Health. Guidelines for implementation of tuberculosis prevention and control program in China 2008 edition. China Union Medical College Press, 2009. (In Chinese) |
[14] |
Yao S, Fang XH. Interpretation and consideration of 2020 edition technical specifications for TB prevention and control in China. J Trop Dis Parasitol, 2020; 18, 138−41, 137. (In Chinese |
[15] |
National Health Commission of the PRC. Technical specifications for tuberculosis prevention and control in China (2020). Technical specifications for tuberculosis prevention and control in China, 2020 edition. 2020. (In Chinese) |
[16] |
Lu W, Zhou Y, Liu JJ. The Progress and achievements of tuberculosis control in China since 1949. Chin J Dis Control Prev, 2019; 23, 754−7, 62. (In Chinese |
[17] |
Bloom G, Gu XY. Health sector reform: lessons from China. Soc Sci Med, 1997; 45, 351−60. doi: 10.1016/S0277-9536(96)00350-4 |
[18] |
Liu JJ. Progress of tuberculosis control program in China. Chinese Medical Association, 2004; 5−9. (In Chinese |
[19] |
Zhao YJ, Wang SY. Promoting the prevention and control strategy of tuberculosis scientifically to achieve "the 13th Five-year Plan" for tuberculosis control program. Chin J Dis Control Prev, 2017; 21, 431−3, 538. (In Chinese |
[20] |
General Office of the State Council of the People's Republic of China. National tuberculosis control plan (2011-2015). Chin Pract J Rural Doct, 2012; 19, 1−3. (In Chinese |
[21] |
Huang F, Cheng SM, Du X, et al. Electronic recording and reporting system for tuberculosis in China: experience and opportunities. J Am Med Inform Assoc, 2014; 21, 938−41. doi: 10.1136/amiajnl-2013-002001 |
[22] |
Census Office of the State Council. China's 2010 census. China Statistics Press. 2012. (In Chinese) |
[23] |
Zhao CF, Gao F, Li QW, et al. The distributional characteristic and growing trend of pancreatic cancer in China. Pancreas, 2019; 48, 309−14. doi: 10.1097/MPA.0000000000001222 |
[24] |
Kim HJ, Luo J, Kim J, et al. Clustering of trend data using joinpoint regression models. Stat Med, 2014; 33, 4087−103. doi: 10.1002/sim.6221 |
[25] |
Cui YR, Shen H, Wang F, et al. A long-term trend study of tuberculosis incidence in China, India and United States 1992–2017: a joinpoint and age–period–cohort analysis. Int J Environ Res Public Health, 2020; 17, 3334. doi: 10.3390/ijerph17093334 |
[26] |
Wang LQ, Wang WB. Temporal trends in notification and mortality of tuberculosis in China, 2004-2019: a joinpoint and age-period-cohort analysis. Int J Environ Res Public Health, 2021; 18, 5607. doi: 10.3390/ijerph18115607 |
[27] |
WHO. National tuberculosis prevalence surveys 2007-2016. WHO. 2021. |
[28] |
Liu SY, Bi YJ, Liu YW. Modeling and dynamic analysis of tuberculosis in mainland China from 1998 to 2017: the effect of DOTS strategy and further control. Theor Biol Med Model, 2020; 17, 6. doi: 10.1186/s12976-020-00124-9 |
[29] |
Wang L, Cheng S, Xu M, et al. Model collaboration between hospitals and public health system to improve tuberculosis control in China. Int J Tuberc Lung Dis, 2009; 13, 1486−92. |
[30] |
Jiang SW, Zhang H, Wang DM, et al. Contribution of the Global Fund's Tuberculosis program to Tuberculosis control in China. Chin J Antituberc, 2014; 36, 305−7. (In Chinese |
[31] |
Schwartz NG, Price SF, Pratt RH, et al. Tuberculosis—United States, 2019. MMWR Morb Mortal Wkly Rep, 2020; 69, 286−9. doi: 10.15585/mmwr.mm6911a3 |
[32] |
Ren TT, Lu PX, Deng GF, et al. 2020 WHO tuberculosis report: key data for China and the whole world. Electron J Emerg Infect Dis, 2020; 5, 280−4. (In Chinese |
[33] |
Ma Y, Lu W, Gao L, et al. To end tuberculosis epidemic needs strengthen the management of screening and preventive treatment of latent tuberculosis infection in high-risk groups. Chin J Antituberc, 2022; 44, 209−14. (In Chinese |
[34] |
Xu CH, Zhang XM, Liu Y, et al. Factors associated with diagnostic delay of pulmonary tuberculosis in China. Biomed Environ Sci, 2022; 35, 73−8. |
[35] |
Li T, Sun YN, Zhang H, et al. Experience and implications of the 2011 Global Fund on international project management. Chin Prev Med, 2015; 16, 728−30. (In Chinese |
[36] |
Deutsch-Feldman M, Pratt RH, Price SF, et al. Tuberculosis—United States, 2020. MMWR Morb Mortal Wkly Rep, 2021; 70, 409−14. doi: 10.15585/mmwr.mm7012a1 |
[37] |
Kwak N, Hwang SS, Yim JJ. Effect of COVID-19 on tuberculosis notification, South Korea. Emerg Infect Dis, 2020; 26, 2506−8. doi: 10.3201/eid2610.202782 |
[38] |
Geng YM, Li G, Zhang LL. The impact of COVID-19 Interventions on influenza and Mycobacterium tuberculosis infection. Front Public Health, 2021; 9, 672568. doi: 10.3389/fpubh.2021.672568 |
[39] |
Huang F, Xia YY, Chen H, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Health West Pac, 2020; 3, 100032. doi: 10.1016/j.lanwpc.2020.100032 |
[40] |
Cheng J, Sun YN, Zhang CY, et al. Incidence and risk factors of tuberculosis among the elderly population in China: a prospective cohort study. Infect Dis Poverty, 2020; 9, 13. doi: 10.1186/s40249-019-0614-9 |
[41] |
Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am, 2010; 24, 751−68. doi: 10.1016/j.idc.2010.04.011 |
[42] |
Yang RL, Liu MY, Jiang H, et al. The epidemiology of pulmonary tuberculosis in children in Mainland China, 2009–2015. Arch Dis Child, 2020; 105, 319−25. doi: 10.1136/archdischild-2019-317635 |
[43] |
Wang YH, Tian Y, Gao JX, et al. Tuberculosis prevalence among university freshmen in Zhengzhou, China, during 2004-2013. Afr Health Sci, 2018; 18, 1109−16. doi: 10.4314/ahs.v18i4.32 |
[44] |
Yang S, Gao Y, Luo W, et al. Spatiotemporal distribution of tuberculosis during urbanization in the new urban area of Nanchang City, China, 2010–2018. Int J Environ Res Public Health, 2019; 16, 4395. doi: 10.3390/ijerph16224395 |
[45] |
Alirol E, Getaz L, Stoll B, et al. Urbanisation and infectious diseases in a globalised world. The Lancet Infect Dis, 2011; 11, 131−41. doi: 10.1016/s1473-3099(10)70223-1 |
[46] |
Yan F, Thomson R, Tang SL, et al. Multiple perspectives on diagnosis delay for tuberculosis from key stakeholders in poor rural China: case study in four provinces. Health Policy, 2007; 82, 186−99. doi: 10.1016/j.healthpol.2006.08.001 |
[47] |
Tao NN, He XC, Zhang XX, et al. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China. Int J Infect Dis, 2017; 65, 8−14. doi: 10.1016/j.ijid.2017.09.019 |
[48] |
Li HM, Cheng B, Chen YC. What causes high costs for rural tuberculosis inpatients? Evidence from five counties in China. BMC Infect Dis, 2020; 20, 501. doi: 10.1186/s12879-020-05235-9 |
[49] |
Li Q, Jiang WX, Wang QL, et al. Non-medical financial burden in tuberculosis care: a cross-sectional survey in rural China. Infect Dis Poverty, 2016; 5, 5. doi: 10.1186/s40249-016-0101-5 |
[50] |
Shang Y, Zhang TT, Wang ZF, et al. Spatial epidemiological characteristics and Exponential smoothing model application of Tuberculosis in Qinghai Plateau, China. Epidemiol Infect, 2022; 150, e37. doi: 10.1017/S0950268822000036 |
[51] |
Li JZ, Li YH, Ye M, et al. Forecasting the tuberculosis incidence using a novel ensemble empirical mode decomposition-based data-driven hybrid model in Tibet, China. Infect Drug Resist, 2021; 14, 1941−55. doi: 10.2147/IDR.S299704 |
[52] |
He XY, Cao MQ, Mahapatra T, et al. Burden of tuberculosis in Xinjiang between 2011 and 2015: a surveillance data-based study. PLoS One, 2017; 12, e0187592. doi: 10.1371/journal.pone.0187592 |
[53] |
Mijiti P, Li YH, Feng X, et al. Prevalence of pulmonary tuberculosis in western China in 2010–11: a population-based, cross-sectional survey. Lancet Glob Health, 2016; 4, e485−94. doi: 10.1016/S2214-109X(16)30074-2 |
[54] |
Zhang JJ, Yang YY, Qiao X, et al. Factors influencing medication nonadherence to pulmonary tuberculosis treatment in Tibet, China: a qualitative study from the patient perspective. Patient Prefer Adherence, 2020; 14, 1149−58. doi: 10.2147/PPA.S252448 |
[55] |
Liu CF, Song YM, He P, et al. Evaluation of multidrug resistant loop-mediated isothermal amplification assay for detecting the drug resistance of Mycobacterium tuberculosis. Biomed Environ Sci, 2021; 34, 616−22. |